China is a high prevalence area of hepatitis B virus (HBV) infection, there are about 90 million chronic HBV infected people in China, and the results of domestic and international studies have fully proved that the viral load in chronic hepatitis B patients is the main reason for determining the progression of the disease and the prognosis, which can only be realized through antiviral treatment. A number of studies have shown that Chinese patients with chronic hepatitis B who are negative for HBV-DNA and undergo HBe seroconversion (commonly referred to as “big three-positive” to “small three-positive”) are in significant remission, and the progression of cirrhosis and the occurrence of primary hepatocellular carcinoma can be significantly reduced. The American Academy of Liver Diseases, the European Association of Liver Diseases, and the American Society for the Prevention of Liver Disease. The clinical guidelines for antiviral therapy formulated by the American Association of Liver Diseases, the European Association of Liver Diseases, and the Asian-Pacific Association of Liver Diseases have proposed three levels of antiviral treatment endpoints: (1) the ideal treatment endpoint is the disappearance of surface antigen (HBsAg); (2) the satisfactory treatment endpoint is the lasting serologic conversion of HBeAg; and (3) the basically satisfactory treatment endpoint is to maintain the undetectable level of HBV-DNA. However, the annual clearance rate of HBsAg by various drugs is less than 5%, so for HBeAg-positive patients, it is more realistic to realize the endpoint of HBeAg serological conversion, which is the most important clinical efficacy assessment standard of antiviral treatment. Currently, there are two main classes of antiviral drugs that are effective against chronic hepatitis B: α-interferon and nucleoside analogs (NAs). In China, more than 2 million patients are taking NAs for antiviral treatment. NAs that have been approved for anti-HBV treatment include lamivudine, adefovir, telbivudine, and entecavir. But the above drugs for 2-5 years, HBeAg serological conversion rate is only 20-40%, and even if the serological conversion occurs to meet the criteria for discontinuation of the drug, discontinuation of the drug one year after the relapse rate is as high as 70% or more; prolonged course of treatment is one of the countermeasures to increase the rate of serological conversion of HBeAg, but at the same time inevitably is the rate of resistance to the drug is also increased. For example, the resistance rate of lamivudine can be up to about 20% per year, and the resistance rate increases with time, and all kinds of NAs can not be avoided. Once resistance occurs, the effectiveness of antiviral drugs is lost, HBV-DNA is reactivated, the frequency of hepatitis relapse is significantly higher than that of those who have not undergone viral mutation, and the frequency of worsening of hepatitis and liver disease-associated serious adverse events is significantly increased, and even cancel out the therapeutic efficacy achieved before. Combination of drugs may be one of the solutions to this dilemma, however, combination therapy with various western drugs that have been evaluated have not been proven to have higher efficacy should, while increasing the risk of multi-drug resistance, adverse drug reactions, and increased cost of efficacy and economy. The main reason is that NAs only inhibit viral replication and cannot solve the difficult problem of immunocompromised (disordered) immunity in patients with chronic hepatitis B. Chinese medicine has its unique advantages in these aspects, and the combination of Chinese and Western medicine antiviral therapy will be one of the main directions of anti-hepatitis B virus treatment in the future. Chinese medicine theory attributes part of the body’s defense function and all innate factors to the kidney, and low immune function is due to the deficiency of the body’s positive qi, the root cause of which lies in the kidney, so the deficiency of the kidney qi plays an important role in the chronicity of HBV infection. A number of clinical studies in our hospital have found that the Chinese medicine Senxian Hepatitis B Spirit, together with the treatment of different NAs, can significantly increase the HBeAg serological conversion rate and sustained response rate, and reduce the occurrence of drug resistance. Hepatitis B Ling is a self-manufactured medicine based on the method of tonifying the kidneys and detoxifying the toxins, which is widely used in the treatment of chronic hepatitis B. Its main ingredients include Codonopsis pilosulae, Astragalus membranaceus, Paeonia lactiflora, Cynodonopsis pilosulae, chaste tree seeds, goji berries, tiger’s stick, snake’s tongue herb and so on. By replenishing the innate energy, the positive energy will be sufficient to keep the evil out and promote the recovery of the immune function of the body, and ultimately eliminate the hepatitis B virus.